

2022	Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, DI BARTOLOMEO M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y, Checkmate 648 Trial Investigators	Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE	35108470
2023	Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez Bravo DP, Taieb J, Karamouzis MV, Ruiz Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, PIETRANTONIO F	Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C	NEW ENGLAND JOURNAL OF MEDICINE	37870968
2022	Sartore Bianchi A, PIETRANTONIO F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, MANCA P, Bergamo F, Tosi F, Mauri G, AMBROSINI M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A	Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial	NATURE MEDICINE	35915157
2022	Elez E, Ros J, Fernández J, Villacampa G, Moreno Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo Ruiz J, Piris Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, RANDON G, Vivancos A, Smits R, Graus D, Perez Lopez R, Cremolini C, Lonardi S, PIETRANTONIO F, Dienstmann R, Tabernero J, Toledo RA	RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer	NATURE MEDICINE	36097219
2024	AMBROSINI M, Rousseau B, MANCA P, Artz O, Marabelle A, André T, Maddalena G, MAZZOLI G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, RANDON G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, PIETRANTONIO F	Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer	ANNALS OF ONCOLOGY	38777726

2022	Antoniotti C, Rossini D, PIETRANTONIO F, Cateau A, Salvatore L, Lonardi S, Boquet I, Tambari S, Marmorino F, Moretto R, AMBROSINI M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, MORANO F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopoulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C, Gono Foundation Investigators	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial	LANCET ONCOLOGY	35636444
2023	Van Cutsem E, DI BARTOLOMEO M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlasakar F, Kawaguchi Y, Ku G	Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study	LANCET ONCOLOGY	37329891
2022	MORANO F, RAIMONDI A, PAGANI F, Lonardi S, Salvatore L, Cremolini C, Murgioni S, RANDON G, PALERMO F, Antonuzzo L, Pella N, Racca P, PRISCIANDARO M, NIGER M, CORTI F, Bergamo F, Zaniboni A, Ratti M, PALAZZO M, Cagnazzo C, Calegari MA, Marmorino F, CAPONE I, CONCA E, BUSICO A, BRICH S, TAMBORINI E, PERRONE F, Di Maio M, MILIONE M, DI BARTOLOMEO M, DE BRAUD F, PIETRANTONIO F	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.	JOURNAL OF CLINICAL ONCOLOGY	35258987
2022	Maron SB, Moya S, MORANO F, Emmett MJ, Chou JF, Sabwa S, Walch H, Peterson B, Schrock AB, Zhang L, Janjigian YY, Chalasani S, Ku GY, Disel U, Enzinger P, Uboha N, Kato S, Yoshino T, Shitara K, Nakamura Y, Saeed A, Kasi PM, Chao J, Lee J, Capanu M, Wainberg Z, Petty R, PIETRANTONIO F, Klempner SJ, Catenacci DVT	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience	JOURNAL OF CLINICAL ONCOLOGY	35349370
2022	Rossini D, Antoniotti C, Lonardi S, PIETRANTONIO F, Moretto R, Antonuzzo L, Boccaccino A, MORANO F, Bruglia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, RANDON G, Murgioni S, Borelli B, Buonadonna A,	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO	JOURNAL OF CLINICAL ONCOLOGY	35666229

	Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C			
2023	Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, ANTISTA M, Toledo R, Martinelli E, PIETRANTONIO F, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E	Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments	ANNALS OF ONCOLOGY	36921693
2024	Lonardi S, PIETRANTONIO F	New options for late-line treatment of metastatic colorectal cancer	NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY	38066100
2023	Lonardi S, Rasola C, LOBEFARO R, Rossini D, Formica V, Scartozzi M, Frassinetti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, RAIMONDI A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, MORANO F, Loupakis F, Buggin F, Zagone V, Fassan M, Cremolini C, Boni L, PIETRANTONIO F, Gono Foundation Investigators	Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation	JOURNAL OF CLINICAL ONCOLOGY	37535876
2024	Antoniotti C, Rossini D, PIETRANTONIO F, Salvatore L, Lonardi S, Tamberi S, Marmorino F, Moretto R, PRISCIANDARO M, Tamburini E, Tortora G, Passardi A, Bergamo F, RAIMONDI A, Ritorto G, Borelli B, Conca V, Ugolini C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Boni L, Galon J, Cremolini C	Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study	JOURNAL OF CLINICAL ONCOLOGY	38865678
2024	Raghav K, Siena S, Takashima A, Kato T, Van Den Eynde M, PIETRANTONIO F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T	Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial	LANCET ONCOLOGY	39116902
2024	RANDON G, Lonardi S, Fassan M, PALERMO F, Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, De Vita F, Bittoni A, Chini C, Spallanzani A, Nappo F, Bethaz V, Strippoli A, Latiano T, Cardellino GG, Giuliani F, MORANO F, NIGER M,	Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial	LANCET ONCOLOGY	39557058

	RAIMONDI A, PRISCIANDARO M, PIRCHER CC, SCIORTINO C, MARCHESI S, GARATTINI SK, AIRÒ G, MICELI R, DI BARTOLOMEO M, PIETRANTONIO F			
2022	VERNIERI C, FUCÀ G, LIGORIO F, HUBER V, VINGIANI A, Iannelli F, RAIMONDI A, Rinchai D, Frigè G, BELFIORE A, LALLI L, CHIODONI C, Cancila V, Zanardi F, Ajazi A, Cortellino S, VALLACCHI V, SQUARCINA P, COVA A, PESCE S, FRATI P, Mall R, Corsetto PA, Rizzo AM, FERRARIS C, FOLLI S, GARASSINO MC, CAPRI G, BIANCHI G, COLOMBO MP, Minucci S, Foiani M, Longo VD, APOLONE G, Torri V, PRUNERI G, Bedognetti D, RIVOLTINI L, DE BRAUD F	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer	CANCER DISCOVERY	34789537
2022	Crisafulli G, Sartore Bianchi A, Lazzari L, PIETRANTONIO F, Amatu A, Macagno M, Barault L, Cassingena A, Bartolini A, Luraghi P, Mauri G, Battuello P, Personeni N, Zampino MG, Pessei V, Vitiello PP, Tosi F, Idotta L, MORANO F, Valtorta E, Bonoldi E, Germano G, Di Nicolantonio F, Marsoni S, Siena S, Bardelli A	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients	CANCER DISCOVERY	35522273
2022	Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fasso M, NIGER M, PIETRANTONIO F, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CcY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Göke J, Tan P	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition	GUT	34433583
2023	PUSCEDDU S, CORTI F, PRINZI N, NICHETTI F, LIEVAR S, BUSICO A, CASCELLA T, LEPORATI R, OLDANI S, PIRCHER CC, COPPA J, Resi V, MILIONE M, MACCAURO M, MICELI R, TAMBORINI E, PERRONE F, SPREAFICO C, NIGER M, MORANO F, PIETRANTONIO F, SEREGNI E, MARIANI L, MAZZAFERRO V, DI LIBERTI G, FUCÀ G, DE BRAUD F, VERNIERI C	Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2	JOURNAL OF HEMATOLOGY & ONCOLOGY	38098114

2023	Yap DWT, LEONE AG, Wong NZH, Zhao JJ, Tey JCS, Sundar R, PIETRANTONIO F	Effectiveness of Immune Checkpoint Inhibitors in Patients with Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups	JAMA ONCOLOGY	36480211
2023	LEONE AG, Trapani D, Schabath MB, Safer JD, Scout NfN, Lambertini M, Berardi R, Marsoni S, Perrone F, Cinieri S, MICELI R, MORANO F, PIETRANTONIO F	Cancer in Transgender and Gender-Diverse Persons: A Review	JAMA ONCOLOGY	36757703
2023	Zhao JJ, PIETRANTONIO F, Sundar R	Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients with Advanced Esophageal Squamous Cell Carcinoma - Reply	JAMA ONCOLOGY	37166787
2024	Zhao JJ, Ong CJ, Srivastava S, Chia DKA, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay ST, Hagihara T, Tan ALK, Teo MCC, Tan QX, Ng G, Tan JW, Ng MCH, Gwee YX, Walsh R, Law JH, Shabbir A, Kim G, Tay Y, Her Z, LEONCINI G, Teh BT, Hong JH, Tay RYK, Teo CB, Dings MPG, Bijlsma M, Lum JHY, Mathur S, PIETRANTONIO F, Blum SM, Van Laarhoven H, Klempner SJ, Yong WP, So JBY, Chen Q, Tan P, Sundar R	Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases	GASTROENTEROLOGY	39147169
2023	Yoshino T, DI BARTOLOMEO M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S, Destiny Crc01 Investigators	Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer	NATURE COMMUNICATIONS	37286557
2023	LEONE AG, Casolino R, Trapani D, MICELI R, Massagrande M, MORANO F, La Verde N, Dalu D, Berardi R, Marsoni S, Lambertini M, Iula B, Carieri E, Converti M, Di Maio M, Beretta GD, Perrone F, PIETRANTONIO F, Cinieri S, Italian Foundation Of Medical Oncology (Fondazione Aiom), Italian Association Of Medical Oncology (Aiom)	Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations	ECLINICALMEDICINE	37877000
2023	MORANO F, PIETRANTONIO F	Anti-Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer-Another Piece to the Puzzle	JAMA NETWORK OPEN	37721757
2022	Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, PIETRANTONIO F, Santini D, Allegrini G, Daniel F, PAGANI F, Antonioti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A,	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature	CANCER TREATMENT REVIEWS	35016085

	Tamburini E, Masi G, Di Maio M, Cremolini C			
2022	PUSCEDDU S, PRINZI N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davi MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, CORTI F, Ricci C, Giacomelli L, Porcu L, Di Maio M, SEREGNI E, MACCAURO M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, SCALORBI F, MILIONE M, SABELLA G, COPPA J, Casadei R, DI BARTOLOMEO M, Falconi M, DE BRAUD F	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors	JAMA NETWORK OPEN	35201309
2024	Scherr AL, Nader L, Xu K, Elssner C, Ridder DA, NICHETTI F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, Hoffmeister Wittmann P, Weiler SME, Korell F, Albrecht T, Schwab M, Isele H, Kessler A, Hüllein J, Seretny A, Ye L, Urbanik T, Welte S, Leblond AL, Heilig CE, Rahbari M, Ali A, Gallage S, Lenoir B, Wilhelm N, Gärtner U, Ogrodnik SJ, Springfield C, Tschaharganeh D, Fröhling S, Longerich T, Schulze Bergkamen H, Jäger D, Brandl L, Schirmacher P, Straub BK, Weber A, De Toni EN, Goeppert B, Heikenwalder M, Jackstadt R, Roessler S, Breuhahn K, Köhler BC	Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC	HEPATOLOGY	37916976
2022	De Miguel Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, MANCA P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	35650597
2022	FUCÀ G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P,	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers	JOURNAL FOR IMMUNOTHERAPY OF CANCER	35110358

	Bergamo F, García MD, MAZZOLI G, PROVENZANO L, Colle R, Svrcek M, AMBROSINI M, RANDON G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, CORTI F, Cremolini C, Overman M, Andre T, PIETRANTONIO F			
2022	Moretto R, Elliott A, Zhang J, Arai H, Germani MM, Conca V, Xiu J, Stafford P, Oberley M, Abraham J, Spetzler D, Rossini D, Antoniotti C, Marshall J, Shields A, Lopes G, Lonardi S, PIETRANTONIO F, Tomasello G, Passardi A, Tamburini E, Santini D, Aprile G, Masi G, Falcone A, Lenz HJ, Korn M, Cremolini C	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications	JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE	34469533
2023	PIETRANTONIO F, MANCA P, Bellomo SE, Corso S, RAIMONDI A, Berrino E, MORANO F, Migliore C, NIGER M, CASTAGNOLI L, PUPA SM, Marchiò C, DI BARTOLOMEO M, Restuccia E, Lambertini C, Tabernero J, Giordano S	HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial	CLINICAL CANCER RESEARCH	36413222
2023	Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, PIETRANTONIO F, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, MORANO F, Papiani G, Tamburini E, Bensi M, Murgioni S, Ross DT, Passardi A, Boquet I, Nielsen TJ, Galon J, Varga MG, Schweitzer BL, Cremolini C	An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer	CLINICAL CANCER RESEARCH	37022350
2023	Gallois C, Landi M, Taieb J, Sroussi M, Saberzadeh Ardestani B, Cazelles A, Lonardi S, Bergamo F, Intini R, Maddalena G, PIETRANTONIO F, CORTI F, AMBROSINI M, MARTINETTI A, Germani MM, Boccaccio C, Vetere G, Mouillet Richard S, De Reynies A, Sinicrope FA, Cremolini C, Laurent Puig P	Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors	CLINICAL CANCER RESEARCH	37439810
2023	RANDON G, PIETRANTONIO F	Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer	CLINICAL CANCER RESEARCH	37594733
2023	Tang TY, NICHETTI F, Kaplan B, Lonardi S, PIETRANTONIO F, Salvatore L, Vivaldi C, Rimassa L, DE BRAUD F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, NIGER M	Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers	CLINICAL CANCER RESEARCH	37773629

2023	Bersani F, Picca F, Morena D, Righi L, Napoli F, Russo M, Oddo D, Rospo G, Negrino C, Castella B, Volante M, Listi A, Zambelli V, Benso F, Tabbò F, Bironzo P, Monteleone E, Poli V, PIETRANTONIO F, Di Nicolantonio F, Bardelli A, Ponzetto C, Novello S, Scagliotti GV, Taulli R	Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	37170152
2023	Guarrera L, Kurosaki M, Garattini SK, Gianni' M, Fasola G, Rossit L, PRISCIANDARO M, DI BARTOLOMEO M, Bolis M, Rizzo P, Nastasi C, Foglia M, Zanetti A, Paroni G, Terao M, Garattini E	Anti-tumor activity of all-trans retinoic acid in gastric-cancer: gene-networks and molecular mechanisms	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH	37951921
2023	Petrelli A, Rizzolio S, PIETRANTONIO F, Bellomo SE, Benelli M, DE CECCO L, Romagnoli D, Berrino E, Orrù C, Ribisi S, Moya Rull D, Migliore C, Conticelli D, Maina IM, Puliga E, Serra V, Pellegrino B, Llop Guevara A, Musolino A, Siena S, Sartore Bianchi A, PRISCIANDARO M, MORANO F, ANTISTA M, Fumagalli U, De Manzoni G, Degiuli M, Baiocchi GL, Amisano MF, Ferrero A, Marchiò C, Corso S, Giordano S	BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors	CANCER RESEARCH	37129948
2023	NASCA V, BARRETTA F, CORTI F, Lonardi S, NIGER M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, AMBROSINI M, MAZZOLI G, Intini R, Overman MJ, MICELI R, PIETRANTONIO F	Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer	JOURNAL FOR IMMUNOTHERAPY OF CANCER	36593068
2023	Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, Ugolini C, Proietti A, Conca V, Kassambara A, PIETRANTONIO F, Salvatore L, Lonardi S, Tamberi S, Tamburini E, Poma AM, Fieschi J, Fontanini G, Masi G, Galon J, Cremolini C	Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: Lessons from the AtezoT RIBE study	JOURNAL FOR IMMUNOTHERAPY OF CANCER	37085190
2023	RANDON G, Aoki Y, Cohen R, PROVENZANO L, NASCA V, Klempner SJ, Maron SB, Cerantola R, Chao J, Fornaro L, FERRARI BRAVO W, GHELARDI F, AMBROSINI M, MANCA P, Salati M, Kawazoe A, Zhu V, Cowzer D, Genovesi V, Lonardi S, Shitara K, André T, PIETRANTONIO F	Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade	JOURNAL FOR IMMUNOTHERAPY OF CANCER	37277193

2023	Shitara K, DI BARTOLOMEO M, Mandala M, Ryu MH, Caglevic C, Olesinski T, Chung HC, Muro K, Goekkurt E, Mcdermott RS, Mansoor W, Wainberg ZA, Shih CS, Kobie J, Nebozhyn M, Cristescu R, Cao ZA, Loboda A, Özgüroğlu M	Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: Exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial	JOURNAL FOR IMMUNOTHERAPY OF CANCER	37399357
2024	NICHETTI F, ROTA S, AMBROSINI P, PIRCHER C, GUSMAROLI E, DROZ DIT BUSSET M, PUSCEDDU S, SPOSITO C, COPPA J, MORANO F, PIETRANTONIO F, DI BARTOLOMEO M, MARIANI L, MAZZAFERRO V, DE BRAUD F, NIGER M	NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer	JAMA NETWORK OPEN	38190183
2024	Ciardiello D, Martinelli E, Troiani T, Mauri G, Rossini D, Martini G, Napolitano S, Famiglietti V, Del Tufo S, Masi G, Santini D, Avallone A, PIETRANTONIO F, Lonardi S, Di Maio M, Zampino MG, Fazio N, Bardelli A, Siena S, Cremolini C, Sartore Bianchi A, Ciardiello F	Anti-EGFR Rechallenge in Patients with Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer A Nonrandomized Controlled Trial	JAMA NETWORK OPEN	38592721
2023	Margonis GA, Boerner T, Bachet JB, Buettner S, Moretto R, Andreatos N, Sartore Bianchi A, Wang J, Kamphues C, Gagniere J, Lonardi S, Løes IM, Wagner D, Spallanzani A, Sasaki K, Burkhart R, PIETRANTONIO F, Pikoulis E, Pawlik TM, Truant S, Orlandi A, Pikouli A, Pella N, Beyer K, Poultides G, Seeliger H, Aucejo FN, Kornprat P, Kaczirek K, Lønning PE, Kreis ME, Wolfgang CL, Weiss MJ, Cremolini C, Benoist S, D'Angelica M	Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions	ANNALS OF SURGERY	36453261
2022	RANDON G, Intini R, Cremolini C, Elez E, Overman MJ, Lee J, MANCA P, Bergamo F, PAGANI F, ANTISTA M, Angerilli V, Ros Montaña FJ, Lavacchi D, Boccaccino A, FUCÀ G, BRICH S, CATTANEO L, Fassan M, PIETRANTONIO F, Lonardi S	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer	EUROPEAN JOURNAL OF CANCER	34933155
2022	Antonioti C, Marmorino F, Boccaccino A, MARTINI S, ANTISTA M, Rossini D, ZUCO V, PRISCIANDARO M, Conca V, Zucchelli G, Borelli B, COSENTINO P, Germani MM, BOSCO MF, Carullo M, Vetere G, Moretto R, Giordano M, Masi G,	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer	EUROPEAN JOURNAL OF CANCER	35231767

	PIETRANTONIO F, ZAFFARONI N, Cremolini C			
2022	Christou N, Bergen ES, Canton C, Le Malicot K, DI BARTOLOMEO M, Galli F, Galli F, Labianca R, Shi Q, Alberts SR, Goldberg RM, Lepage C, Sinicrope FA, Taieb J	Impact of diabetes and metformin use on recurrence and outcome in stage II–III colon cancer patients—A pooled analysis of three adjuvant trials	EUROPEAN JOURNAL OF CANCER	35279470
2022	Antoniotti C, Germani MM, Rossini D, Lonardi S, PIETRANTONIO F, Santini D, Marmorino F, Allegrini G, Daniel F, RAIMONDI A, Borelli B, Zaniboni A, Conca V, Abraham J, Spetzler D, Maiello E, Boccaccino A, Passardi A, Giordano M, Tamburini E, Korn MW, Masi G, Cremolini C	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.	EUROPEAN JOURNAL OF CANCER	35366570
2022	Rossini D, Germani MM, Lonardi S, PIETRANTONIO F, Dell'Aquila E, Borelli B, Allegrini G, Maddalena G, RANDON G, Marmorino F, Zaniboni A, Buonadonna A, Boccaccino A, Conca V, Antoniotti C, Passardi A, Masi G, Cremolini C	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies	EUROPEAN JOURNAL OF CANCER	35594613
2022	Rimini M, Macarulla T, Burgio V, Lonardi S, NIGER M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Nappo F, NICHETTI F, Lai E, Valgiusti M, Cappetta A, Febregat C, Fassan M, DE BRAUD F, Puzzoni M, Frassinetti GL, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei Gardini A	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum- based chemotherapy in patients with intrahepatic cholangiocarcinoma	EUROPEAN JOURNAL OF CANCER	35749808
2022	MAZZOLI G, Cohen R, Lonardi S, CORTI F, Elez E, Fakih M, Jayachandran P, Colle R, Shah AT, Salati M, Fenocchio E, Salvatore L, AMBROSINI M, Ros J, Intini R, Cremolini C, Overman MJ, André T, PIETRANTONIO F	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer	EUROPEAN JOURNAL OF CANCER	35777274
2022	Rimini M, Loi E, Fabregat Franco C, Burgio V, Lonardi S, NIGER M, Scartozzi M, Raposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, NICHETTI F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Zavattari P, Casadei Gardini A	Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1- mutated clusters	EUROPEAN JOURNAL OF CANCER	36182816
2024	RANDON G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, NICHETTI F, GHELARDI F, NASCA V,	Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING- HER2 Study	CLINICAL CANCER RESEARCH	37610454

	Bergamo F, Conca V, Ros J, Bando H, Maddalena G, OLDANI S, PRISCIANDARO M, RAIMONDI A, Schrock AB, AGNELLI L, Walch H, Yoshino T, PIETRANTONIO F			
2024	Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne JC, Tunariu N, Hong SP, Marchetti S, Khan K, Fontana E, Angerilli V, Delrieux M, Nava Rodrigues D, Procaccio L, Rao S, Watkins D, Starling N, Chau I, Braconi C, Fotiadis N, Begum R, Guppy N, Howell L, Valenti M, Cribbes S, Kolozsvari B, Kirkin V, Lonardi S, Ghidini M, Passalacqua R, Elghadi R, Magnani L, Pinato DJ, Di Maggio F, GHELARDI F, SOTTOTETTI E, Vetere G, Ciraci P, Vlachogiannis G, PIETRANTONIO F, Cremolini C, Cortellini A, Loupakis F, Fassin M, Valeri N	Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer	CLINICAL CANCER RESEARCH	38376926
2022	MANCA P, CORALLO S, Lonardi S, FUCÀ G, BUSICO A, LEONE AG, CORTI F, Antoniotti C, Procaccio L, Smirardo V, Ratti M, Murialdo R, Racca P, PAGANI F, RANDON G, MARTINETTI A, SOTTOTETTI E, PRISCIANDARO M, AMBROSINI M, RAIMONDI A, MORANO F, PIETRANTONIO F	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.	BRITISH JOURNAL OF CANCER	34811502
2022	Moretto R, Elliott A, Rossini D, Intini R, Conca V, PIETRANTONIO F, Sartore Bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, CORTI F, Mauri G, Fassin M, Masi G, Brodskiy P, Lenz HJ, Shields A, Lonardi S, Korn M, Cremolini C	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?	BRITISH JOURNAL OF CANCER	35665778
2023	Orsi G, Cavaliere A, Tortora G, Lonardi S, Macchini M, Di Marco M, Giordano G, Vasile E, Scartozzi M, Bozzarelli S, Noventa S, Rodriquez MG, Militello AM, Rapposelli IG, Garajova I, De Lorenzo S, Merelli B, Bittoni A, Salvatore L, Procaccio L, Paratore C, Spallanzani A, Peretti U, NIGER M, Giommoni E, Bernardini I, Tamburini E, Bernardino K, Forti L, Valente MM, Cascinu S, Milella M, Reni M	Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)	BRITISH JOURNAL OF CANCER	36482190

2023	Moretto R, Germani MM, Giordano M, Conca V, Proietti A, Niccoli C, PIETRANTONIO F, Lonardi S, Tamburini E, Zaniboni A, Passardi A, Latiano TP, Fanotto V, Di Donato S, PRISCIANDARO M, Bergamo F, Masi G, Fontanini G, Ugolini C, Cremolini C	Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development	BRITISH JOURNAL OF CANCER	36759721
2023	Pretta A, Ziranu P, Giampieri R, Pinna G, RANDON G, Donisi C, Ravarino A, Loi F, Deias G, Palmas E, Pretta G, MORANO F, Semonella F, Mariani S, Deidda MA, Pusceddu V, Puzzoni M, Lai E, Solinas C, Restivo A, Zorcolo L, Barbara R, Berardi R, Faa G, PIETRANTONIO F, Scartozzi M	Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy	BRITISH JOURNAL OF CANCER	37749283
2022	Hoffmeister Wittmann P, Mock A, NICHETTI F, Korell F, Heilig CE, Scherr AL, Günther M, Albrecht T, Kelmendi E, Xu K, Nader L, Kessler A, Schmitt N, Fritzsche S, Weiler S, Sobol B, Stenzinger A, Boeck S, Westphalen CB, Schulze Osthoff K, Trojan J, Kindler T, Weichert W, Spiekermann K, Bitzer M, Folprecht G, Illert AL, Boerries M, Klauschen F, Ochsenreither S, Siveke J, Bauer S, Glimm H, Brors B, Hülle J, Hübschmann D, Uhrig S, Horak P, Kreutzfeldt S, Banales JM, Springfield C, Jäger D, Schirmacher P, Roessler S, Ormanns S, Goeppert B, Fröhling S, Köhler BC	Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma	LIVER INTERNATIONAL	35983950
2024	Margonis GA, Wang JJ, Boerner T, Moretto R, Buettner S, Andreatos N, Gagnière J, Wagner D, Løes IM, Bergamo F, PIETRANTONIO F, Scartozzi M, Spallanzani A, Vincenzi B, Antoniou E, Pikoulis E, Sartore Bianchi A, Stasinou G, Sasaki K, Pawlik TM, Orlandi A, Pella N, Fitschek F, Kaczirek K, Dupré A, Pozios I, Beyer K, Kornprat P, Aucejo FN, Burkhart R, Weiss MJ, Lønning PE, Poultides G, Cremolini C, Kreis ME, D'Angelica M	Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study	BRITISH JOURNAL OF SURGERY	39051667
2024	MACCAURO M, CUOMO M, Bauckneht M, BAGNALASTA M, MAZZAGLIA S, SCALORBI F, ARGIROFFI G, KIRIENKO M, LORENZONI A, ALIBERTI	The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING	39235614

	G, PUSCEDDU S, GIUSEPPINA C, MATTEO GE, SEREGNI E, CHIESA C			
2023	Prete AA, MANCA P, Messina M, Formica V, Frassinetti GL, Zampino MG, Corsi DC, Orciuolo C, PRISCIANDARO M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, MORANO F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, MILIONE M, Cremolini C, Fassan M, PIETRANTONIO F, Lonardi S	Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study	EUROPEAN JOURNAL OF CANCER	36753836
2023	MANCA P, CORTI F, Intini R, MAZZOLI G, MICELI R, Germani MM, Bergamo F, AMBROSINI M, CRISTARELLA E, Cerantola R, Boccaccio C, Ricagno G, GHELARDI F, RANDON G, LEONCINI G, MILIONE M, Fassan M, Cremolini C, Lonardi S, PIETRANTONIO F	Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors	EUROPEAN JOURNAL OF CANCER	37099945
2023	Taïeb J, Sayah L, Heinrich K, Kunzmann V, Boileve A, Cirkel G, Lonardi S, Chibaudel B, Turpin A, Beller T, Hautefeuille V, Vivaldi C, Mazard T, Bauguion L, NIGER M, Prager GW, Coutzac C, Benedikt Westphalen C, Auclin E, Pilla L	Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort	EUROPEAN JOURNAL OF CANCER	37229836
2023	Boccaccino A, Rossini D, RAIMONDI A, Carullo M, Lonardi S, MORANO F, Santini D, Tomasello G, NIGER M, Zaniboni A, Daniel F, Bustreo S, Procaccio L, Clavarezza M, Cupini S, Libertini M, PALERMO F, PIETRANTONIO F, Cremolini C	Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials	EUROPEAN JOURNAL OF CANCER	37301718
2023	RAIMONDI A, NICHETTI F, Stahler A, Wasan HS, Aranda E, RANDON G, Kurreck A, Meade AM, Díaz Rubio E, NIGER M, Stintzing S, PALERMO F, Trarbach T, PRISCIANDARO M, Sommerhäuser G, Fisher D, MORANO F, PIETRANTONIO F, Modest DP	Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials	EUROPEAN JOURNAL OF CANCER	37441940
2023	Goodman RS, DI GUARDO L, MAURICHI A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czaplá J, SPAGNOLETTI A, AMBROSINI M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojanello C, Ascierto PA, Schadendorf D,	Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma	EUROPEAN JOURNAL OF CANCER	37827067

	Warburton L, Menzies AM, SANTINAMI M, Johnson DB			
2023	PIETRANTONIO F, Bergamo F, Rossini D, GHELARDI F, De Grandis MC, Germani MM, Barsotti G, Formica V, Frassinetti GL, Boscolo G, Cinieri S, Di Donato S, Antonuzzo L, Antonioti C, AMBROSINI M, Piva VM, NICHETTI F, Fassan M, Cremolini C, Lonardi S	Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV	EUROPEAN JOURNAL OF CANCER	37924647
2022	Fuchs CS, Özgüroğlu M, Bang YJ, DI BARTOLOMEO M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, Muro K, Van Cutsem E, Elme A, Thuss Patience P, Chau I, Ohtsu A, Bhagia P, Wang A, Shih CS, Shitara K	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial	GASTRIC CANCER	34468869
2022	Rosati G, Cella CA, Cavanna L, Codecà C, PRISCIANDARO M, Mosconi S, Luchena G, Silvestris N, Bernardini I, Casaretti R, Zoratto F, Amoroso D, Ciarlo A, Barni S, Cascinu S, Davite C, Di Sanzo A, Casolaro A, Bilancia D, Labianca R	A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.	GASTRIC CANCER	35352176
2022	Grizzi G, Petrelli F, DI BARTOLOMEO M, Viti M, Texeira Moraes M, Luciani A, Passalacqua R, Ghidini M, Tomasello G, Baiocchi GL, Celotti A	Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis	GASTRIC CANCER	35704113
2024	Parisi A, Delaunay B, Pinterpe G, Hollebecque A, Blanc JF, Bouattour M, Assenat E, Ben Abdelghani M, Sarabi M, NIGER M, Vivaldi C, Mandalà M, Palloni A, Bensi M, Garattini SK, Tougeron D, Combe P, Salati M, Rimini M, Cella CA, Tucci M, Diana A, Mori E, Longarini R, Artru P, Roth G, Evesque L, Vienne A, Turpin A, Huret S, Bourgeois V, Herve C, Paulon R, Stacoffe M, Malka D, Neuzillet C, Edeline J, Lievre A, Guimbaud R, Chapda MCP, Rimassa L, Giampieri R, Valle J, Berardi R, Fares N	Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies	EUROPEAN JOURNAL OF CANCER	38340384
2024	RAIMONDI A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, RANDON G, Kook MC, An JY, Grabsch HI, PRISCIANDARO M, NICHETTI F, Noh SH, Sohn TS, Kim S, Wotherspoon A, MORANO F, Cunningham D, Lee J, Cheong JH, Smyth EC, PIETRANTONIO F	Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials	EUROPEAN JOURNAL OF CANCER	38598921

2024	Liverani C, Bongiovanni A, Foca F, Bergamo F, Leo S, PUSCEDDU S, Gelsomino F, Brizzi MP, Di Meglio G, Spada F, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T	A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas	EUROPEAN JOURNAL OF CANCER	39002347
2024	Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, NICHETTI F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquez MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, NIGER M, Balsano R, Tonini G, Kang M, Bekaii Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei Gardini A	Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population	EUROPEAN JOURNAL OF CANCER	39002348
2024	Laganà M, Habra MA, Remde H, Almeida MQ, Cosentini D, PUSCEDDU S, Grana CM, Corssmit EPM, Bongiovanni A, De Filpo G, Lim ES, Zamparini M, Grisanti S, Deutschbein T, Fassnacht M, Fagundes GFC, Pereira MAA, OLDANI S, ROTA S, PRINZI N, Jimenez C, Berruti A	Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma	EUROPEAN JOURNAL OF CANCER	39047533
2024	NASCA V, PRINZI N, COPPA J, PRISCIANDARO M, OLDANI S, GHELARDI F, CONCA E, CAPONE I, BUSICO A, PERRONE F, TAMBORINI E, SABELLA G, GRECO G, GRECO FG, Tafuto S, PROCOPIO G, MORANO F, NIGER M, MACCAURO M, MILIONE M, DE BRAUD F, PIETRANTONIO F, PUSCEDDU S	Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial	EUROPEAN JOURNAL OF CANCER	39128186
2024	AMBROSINI M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G,	BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer	EUROPEAN JOURNAL OF CANCER	39216175

	Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, PIETRANTONIO F, Lonardi S, Gallois C, Taieb J			
2024	Margalit O, Stemmer A, Chapin WJ, Shacham Shmueli E, Kopetz S, Andre T, Overman MJ, PIETRANTONIO F, Boursi B	Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients	EUROPEAN JOURNAL OF CANCER	39316932
2022	NIGER M, NICHETTI F, Casadei Gardini A, MORANO F, PIRCHER C, TAMBORINI E, PERRONE F, Canale M, Lipka DB, VINGIANI A, AGNELLI L, Dobberkau A, Hüllelin J, Korell F, Heilig CE, PUSCEDDU S, CORTI F, DROZ M, Ulivi P, PRISCIANDARO M, ANTISTA M, BINI M, CATTANEO L, MILIONE M, Glimm H, Köhler BC, PRUNERI G, Hübschmann D, Fröhling S, MAZZAFERRO V, PIETRANTONIO F, DI BARTOLOMEO M, DE BRAUD F	MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers	MOLECULAR ONCOLOGY	35621918
2023	Bergen ES, Pilla L, Auclin E, Ilhan Mutlu A, Prager GW, PIETRANTONIO F, ANTISTA M, GHELARDI F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanen A	Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study	GASTRIC CANCER	36881202
2023	Fornaro L, Lonardi S, Catanese S, Nappo F, PIETRANTONIO F, Pellino A, Angerilli V, Signorini F, Salani F, Murgioni S, Neculaescu IA, Bruno R, Vivaldi C, Ricagno G, Masi G, Bergamo F, Ugolini C, Fassan M	Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action	GASTRIC CANCER	37382783
2022	RAIMONDI A, RANDON G, PRISCIANDARO M, PAGANI F, Lonardi S, Antoniotti C, Bozzarelli S, Sartore Bianchi A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Petrelli F, Antonuzzo L, Giordano M, Rossi A, DI BARTOLOMEO M, Di Maio M, PIETRANTONIO F, MORANO F	Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial	INTERNATIONAL JOURNAL OF CANCER	35678328
2022	NIGER M, NICHETTI F, Casadei Gardini A, Rizzato MD, PIRCHER C, BINI M, FRANZA A, Rimini M, Burgio V, SPOSETTI C, Fornaro L, Rapposelli IG, D'Amico FE, Aprile G, Vivaldi C, Frassinetti	Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study	INTERNATIONAL JOURNAL OF CANCER	35723131

	GL, MILIONE M, LEONCINI G, Cappetta A, Vasile E, Fassan M, MORANO F, PERRONE F, TAMBORINI E, PRUNERI G, Lonardi S, MAZZAFERRO V, PIETRANTONIO F, DI BARTOLOMEO M, DE BRAUD F			
2023	Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco MC, Spada M, Cordio S, Aprile G, Cardellino GG, Maiello E, Bernardini I, Ghidini M, Bozzarelli S, Macchini M, Orsi G, De Simone I, Rulli E, Porcu L, Torri V, Pinto C, Garibaldi Study Group	Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey	ESMO OPEN	36731325
2023	LEONE AG, MICELI R, Trapani D, Massagrande M, MORANO F, Marsoni S, La Verde N, Berardi R, Casolino R, Lambertini M, Dalu D, Di Maio M, Beretta GD, Perrone F, Cinieri S, PIETRANTONIO F	Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology	ESMO OPEN	37270870
2023	Grassi E, Zingaretti C, Petracci E, Corbelli J, Papiani G, Banchelli I, Valli I, Frassinetti GL, Passardi A, DI BARTOLOMEO M, PIETRANTONIO F, Gelsomino F, Carandina I, Banzi M, Martella L, Bonetti AV, Boccaccino A, Molinari C, Marisi G, Ugolini G, Nanni O, Tamberi S	Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial	ESMO OPEN	37774508
2024	Berardi R, Rossi F, Papa R, Appetecchia M, Baggio G, Bianchini M, Mazzei T, Maria Moretti A, Ortona E, PIETRANTONIO F, Tarantino V, Vavalà T, Cinieri S	Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM)	ESMO OPEN	38394984
2024	Germani MM, Vetere G, Santamaria F, Intini R, GHELARDI F, Bensi M, Boccaccino A, Minelli A, Carullo M, Ciraci P, Passardi A, Santucci S, Giampieri R, Persano M, Fenocchio E, Puccini A, Lonardi S, PIETRANTONIO F, Salvatore L, Cremolini C	Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset	ESMO OPEN	38613911
2024	Marinelli D, Sabatini A, Bengala E, Ciurluini F, Picone V, Santini D, PIETRANTONIO F, Rossini D, Cremolini C	Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer—single versus double checkpoint inhibition	ESMO OPEN	38833965
2024	Platt JR, Allotey J, Alouani E, Glasbey J, Intini R, Lonardi S, MAZZOLI G, Militello AM, Modest DP, Palle J, PIETRANTONIO F, Riyad K, Samuel L, Schulze AV, Shiu KK, Taieb J, Tolan DJM, West	Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series	ESMO OPEN	39241497

	NP, Westwood AC, Williams CJM, Seligmann JF			
2024	Tosi F, Salvatore L, Tamburini E, Artale S, Lonardi S, Marchetti S, Pastorino A, PIETRANTONIO F, Puccini A, Rojas Llimpe FL, Vincenzi B, Mariano S, Negri F, Bencardino K, Pinto C, Aschele C, Siena S	Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study	ESMO OPEN	39357124
2024	LEONE AG, Mai AS, Fong KY, Yap DWT, Kato K, Smyth E, Moehler M, Seong JTC, Sundar R, Zhao JJ, PIETRANTONIO F	Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups	ESMO OPEN	39426081
2022	LEONE AG, Petrelli F, Ghidini A, RAIMONDI A, Smyth EC, PIETRANTONIO F	Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score	ESMO OPEN	35093742
2022	LOBEFARO R, ROTA S, Porcu L, BRUNELLI C, ALFIERI S, ZITO E, TAGLIALATELA I, AMBROSINI M, SPAGNOLETTI A, ZIMATORE M, FATUZZO G, LAVECCHIA F, BORREANI C, APOLONE G, DE BRAUD F, PLATANIA M	Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors.	ESMO OPEN	35366489